PMID- 24733427
OWN - NLM
STAT- MEDLINE
DCOM- 20141211
LR  - 20211021
IS  - 1432-1262 (Electronic)
IS  - 0179-1958 (Linking)
VI  - 29
IP  - 6
DP  - 2014 Jun
TI  - Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma.
PG  - 663-71
LID - 10.1007/s00384-014-1857-3 [doi]
AB  - PURPOSE: The molecular chaperone heat shock protein 90 (HSP90) plays an important 
      role in several types of tumors also participating in the modulation of the 
      activity of receptor tyrosine kinases activity such as members of the Her family. 
      We evaluated the significance of HSP90 and Her2 expression in colon cancer. 
      METHODS: HSP90 and Her2 expression was determined by immunohistochemistry and by 
      fluorescence in situ hybridization (FISH) on 355 primary resected colon 
      carcinomas. Results were correlated with pathologic features (Union for 
      International Cancer Control (UICC) pTNM category, tumor localisation, tumor 
      differentiation), additional molecular genetic characteristics (BRAF, KRAS 
      mutational status, mismatch repair genes (MMR)), and survival. RESULTS: HSP90 
      immunoreactivity was observed in various degrees. Fifty-one cases (14 %) were 
      positive for Her2 (score 2+ and 3+) with 16/43 cases with Her2 2+ staining 
      pattern showing amplification of Her2 determined by FISH. There was a significant 
      correlation between high HSP90 expression and Her2 overexpression (p = 0.011). 
      High HSP90 expression was associated with earlier tumor stages (p = 0.019), 
      absence of lymph node (p = 0.006), and absence of distant metastases (p = 0.001). 
      Patients with high tumoral HSP90 levels had a better survival (p = 0.032), but 
      this was not independent from other prognostic relevant pathologic parameters. 
      Her2 expression was not associated with any of the investigated 
      histopathological, molecular, or clinical parameters. CONCLUSIONS: High HSP90 
      levels are reflecting lower malignant potential in colon cancer. Her2 positivity 
      can be observed in a small number of cases. Targeting HSP90 and/or Her2 may be an 
      alternative therapeutic approach in colon cancer in a subset of patients.
FAU - Drecoll, Enken
AU  - Drecoll E
AD  - Institute of Pathology, Technische Universitat Munchen, Munich, Germany.
FAU - Nitsche, Ulrich
AU  - Nitsche U
FAU - Bauer, Karina
AU  - Bauer K
FAU - Berezowska, Sabina
AU  - Berezowska S
FAU - Slotta-Huspenina, Julia
AU  - Slotta-Huspenina J
FAU - Rosenberg, Robert
AU  - Rosenberg R
FAU - Langer, Rupert
AU  - Langer R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140415
PL  - Germany
TA  - Int J Colorectal Dis
JT  - International journal of colorectal disease
JID - 8607899
RN  - 0 (HSP90 Heat-Shock Proteins)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Colonic Neoplasms/genetics/*metabolism/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - HSP90 Heat-Shock Proteins/genetics/*metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Survival Analysis
EDAT- 2014/04/16 06:00
MHDA- 2014/12/17 06:00
CRDT- 2014/04/16 06:00
PHST- 2014/04/02 00:00 [accepted]
PHST- 2014/04/16 06:00 [entrez]
PHST- 2014/04/16 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - 10.1007/s00384-014-1857-3 [doi]
PST - ppublish
SO  - Int J Colorectal Dis. 2014 Jun;29(6):663-71. doi: 10.1007/s00384-014-1857-3. Epub 
      2014 Apr 15.